Amphastar Pharmaceuticals Prices Offering Of $300M Of 2.00% Convertible Senior Notes Due 2029
Portfolio Pulse from Benzinga Newsdesk
Amphastar Pharmaceuticals has priced its offering of $300M of 2.00% convertible senior notes due 2029.
September 13, 2023 | 6:41 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Amphastar Pharmaceuticals has priced its offering of $300M of 2.00% convertible senior notes due 2029. This could potentially dilute existing shareholders' equity.
The issuance of convertible notes can lead to dilution of existing shareholders' equity if the notes are converted into common shares. This could potentially put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100